Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breast CARE Study
2006-004008-38Phase 2Terminated
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and Rhenium-188-HEDP in breast cancer and bone metastases, sponsored by University Medical Center Utrecht. Primary endpoints: Maximum tolerated dose of rhenium-188-HEDP in combination with capecitabine and Pain efficacy. Started Sep 2006; status: terminated.
02
Drugs
capecitabineRhenium-188-HEDP
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on 2006-004008-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004008-38.